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Abstract 
Background: Assembly of heterologous metabolic pathways is commonly required to generate microbial cell facto-
ries for industrial production of both commodity chemicals (including biofuels) and high-value chemicals. Promoter-
mediated transcriptional regulation coordinates the expression of the individual components of these heterologous 
pathways. Expression patterns vary during culture as conditions change, and this can influence yeast physiology and 
productivity in both positive and negative ways. Well-characterized strategies are required for matching transcrip-
tional regulation with desired output across changing culture conditions.
Results: Here, constitutive and inducible regulatory mechanisms were examined to optimize synthetic isoprenoid 
metabolic pathway modules for production of trans-nerolidol, an acyclic sesquiterpene alcohol, in yeast. The choice of 
regulatory system significantly affected physiological features (growth and productivity) over batch cultivation. Use of 
constitutive promoters resulted in poor growth during the exponential phase. Delaying expression of the assembled 
metabolic modules using the copper-inducible CUP1 promoter resulted in a 1.6-fold increase in the exponential-
phase growth rate and a twofold increase in productivity in the post-exponential phase. However, repeated use of the 
CUP1 promoter in multiple expression cassettes resulted in genetic instability. A diauxie-inducible expression system, 
based on an engineered GAL regulatory circuit and a set of four different GAL promoters, was characterized and 
employed to assemble nerolidol synthetic metabolic modules. Nerolidol production was further improved by 60% 
to 392 mg L−1 using this approach. Various carbon source systems were investigated in batch/fed-batch cultivation 
to regulate induction through the GAL system; final nerolidol titres of 4–5.5 g L−1 were achieved, depending on the 
conditions.
Conclusion: Direct comparison of different transcriptional regulatory mechanisms clearly demonstrated that cou-
pling the output strength to the fermentation stage is important to optimize the growth fitness and overall produc-
tivities of engineered cells in industrially relevant processes. Applying different well-characterized promoters with the 
same induction behaviour mitigates against the risks of homologous sequence-mediated genetic instability. Using 
these approaches, we significantly improved sesquiterpene production in yeast.
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Background
Metabolic engineering and synthetic biology are now 
routinely used for the engineering of microorganisms 
for industrial production of desirable chemicals, includ-
ing fuels and biochemicals [1–3]. In the first instance, 
metabolic pathway flux towards the desired product 
is optimized by introduction of enzymes with the best 
catalytic efficiency (which are often heterologous) [4–6]. 
Expression levels of these enzymes are then titrated for 
optimal pathway balance, in combination with other 
metabolic engineering strategies to redirect carbon in 
the metabolic network [7–9]. Complicating matters, the 
activities of synthetic pathways should be coordinated 
with the dynamic fermentation conditions and process 
stage [10]. Imbalance in pathway flux can have a negative 
effect on cell physiology (e.g. growth rate) and on prod-
uct titre [11]. Coordination can be controlled at the tran-
scriptional level to regulate gene expression (and hence, 
enzyme activity). However, there is only limited informa-
tion available on the dynamic behaviour of promoters 
across the range of conditions that occur in industrial fer-
mentation processes.
The budding yeast Saccharomyces cerevisiae is a com-
mon engineering platform for production of high-
value plant terpenoids. Terpenoids are a diverse class 
of chemicals naturally synthesized from the univer-
sal 5-carbon precursors, isopentenyl pyrophosphate 
(IPP) and dimethylallyl pyrophosphate (DMAPP) [12]. 
The sesquiterpene sub-class of terpenes have 15 car-
bon atoms and are synthesized from farnesyl pyrophos-
phate (FPP), which is condensed from one molecule of 
DMAPP and two molecules of IPP. Sesquiterpenes have 
broad industrial applications, including as fragrances, 
flavours, pharmaceuticals, solvents and fuels. A generic 
set of metabolic engineering approaches can be used to 
improve sesquiterpene production (Fig. 1) [13–16]. First, 
high-level production of terpenoids requires improved 
flux from central carbon metabolism to the sesquiter-
pene precursor FPP [16–23]. This is typically achieved 
by augmenting the mevalonate (MVA) pathway through 
overexpression or heterologous expression of individual 
genes (including farnesyl pyrophosphate synthase, FPPS). 
Enhanced MVA pathway activity causes squalene accu-
mulation [23–25] and it is necessary to constrain the 
flux-competing squalene synthase to redirect FPP flux 
away from sterol production and towards sesquiterpene 
production (Fig.  1). This can be achieved by decreasing 
activity of the FPP-consuming enzyme squalene synthase, 
either through engineered protein degradation [23] or 
transcriptional down-regulation [16, 26, 27]. These steps 
provide the basic principles of pathway optimization for 
sesquiterpene production in yeast.
An ideal microbial cell factory should simultaneously 
exhibit high specific production rate and high specific 
growth rate in a batch cultivation [28]. However, these 
two objectives are commonly incompatible due to the 
metabolic burden and/or metabolic imbalance found 
in the presence of engineered pathways [29–31]. An 
alternative option is to separate growth and production 
phases [31]. This can be achieved by induction of syn-
thetic pathway genes upon an environmental stimulus 
occurring after sufficient biomass is accumulated [32].
Regulation of gene expression across a batch cultivation 
(expression pattern) is delicately controlled by the gene 
promoter, transcriptional regulatory networks and the 
environmental inputs (usually the cultivation conditions, 
















Fig. 1 Metabolic pathways for trans-nerolidol (sesquiterpene) production in yeast. ACS2 acetyl-CoA synthase, EfmvaE Enterococcus faecalis 
acetoacetyl-CoA thiolase/HMG-CoA reductase, EfmvaS E. faecalis HMG-CoA synthase, HMG2 HMG-CoA reductase 2, ERG12 mevalonate kinase, ERG8 
phosphomevalonate kinase, MVD1 mevalonate pyrophosphate decarboxylase, IDI1 isopentenyl diphosphate:dimethylallyl diphosphate isomerase, 
ERG20 farnesyl pyrophosphate synthetase, AcNES1 Actinidia chinensis tran-nerolidol synthase, ERG9 squalene synthase, IPP isopentenyl pyrophos-
phate, DMAPP dimethylallyl pyrophosphate, FPP farnesyl pyrophosphate. Dashed arrow means multiple biochemical steps
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including activator/repressor concentration in cultures) 
[33–36]. Native promoters and regulatory networks can 
readily be used for metabolic pathway construction and 
optimization if their response conditions are well char-
acterized. Several promoters have been well character-
ized to achieve inducible gene expression systems in 
yeast; these include a copper-inducible promoter (PCUP1, 
induced by high concentration of copper ion), galactose-
inducible promoters (the bi-directional PGAL1 and PGAL10 
promoters, de-repressed in the absence of glucose and 
induced when galactose is present), a sucrose-inducible 
promoter (PSUC1, de-repressed in the absence of glucose 
and induced when sucrose is present), a high-affinity 
hexose transporter promoter (PHXT7, induced when glu-
cose levels are low) and heat shock transcriptional factor 
Hsf1p-mediated promoters (PSSA1 and PHSP26) [33, 36–
42]. In addition, sophisticated synthetic regulatory cir-
cuits have been designed, including circuits that respond 
to cell density via an engineered quorum-sensing system 
[32] and circuits that are activated by product feedback 
[43]. These promoters and regulatory networks can be 
further explored for optimizing gene expression regula-
tion in metabolic engineering.
Trans-nerolidol is a sesquiterpene alcohol with applica-
tions as fragrance, flavour, precursor for synthetic vita-
min E/K1 and others [23]. Previously, we engineered a 
trans-nerolidol production pathway in yeast in concert 
with MVA pathway augmentation and a protein-medi-
ated flux down-regulation strategy at squalene synthase 
[23]. We achieved a titre of  ~100  mg  L−1, but observed 
a decreased growth rate when using constitutive over-
expression of genes. To attain high-level production of 
nerolidol without a growth defect, further metabolic 
engineering is required. In this work, we engineered 
transcriptional regulation module that responds to bio-
process conditions to optimize growth and production 
for improved nerolidol titre, in combination with meta-
bolic pathway optimization.
Results
Constitutive expression of genes results in decreased 
growth rates and constrains product titres
In our previous work, nerolidol production was improved 
by heterologously expressing more efficient upper MVA 
pathway genes from Enterococcus faecalis (EfmvaS and 
EfmvaE), overexpressing the yeast lower MVA path-
way genes and FPP synthase and destabilizing squalene 
synthase (Erg9p) [23]. The resulting strain (Table  1) 
produced 104 ± 35 mg L−1 nerolidol over 72 h in batch 
cultivation on minimal medium with 20  g L−1 glucose. 
All of the genes, including nerolidol synthase (AcNES1) 
were overexpressed from plasmids using promoters with 
constitutive activity (PRPL4A for EfmvaS, PRPL15A for Efm-
vaE, PRPL8B for ERG12, PSSB1 for ERG8, PRPL3 for MVD1, 
PYEF3 for IDI1, PTEF2 for ERG20 and PTEF1 for AcNES1; 
Tables  1 and 2). These promoters exhibit high-level 
activities in the exponential phase when glucose is avail-
able, but dramatically decreased activities when glucose 
Table 1 S. cerevisiae strains used in this work
Symbol > or < indicates the direction of open reading frames
a the plasmid pPMVAd36 was transformed
Strain Genotype Resource/reference
CEN.PK2-1C MATa ura3-52 trp1-289 leu2-3,112 his3Δ 1 [44]
CEN.PK113-5D MATa ura3-52 [44]
CEN.PK113-7D MATa [44]
ILHA series strains
oH5 oURA3 derivative; ERG9(1333, 1335)::yEGFP-CLN2PEST-TURA3-loxP-KlURA3-loxP [23]
N6D oH5 derivative; [pPMVAu8] [pPMVAd3] [pJT1] [23]
NC1D oH5 derivative; [pPMVAugw] [TRP1]a [pJT3] This work
o391 CEN.PK2-1C derivative; HMG2K6R(−152 ,−1)::HIS3-TEFM1<EfmvaS<PGAL1–PGAL10>ACS2>TACS2–PGAL2>EfmvaE>T
EBS1–PGAL7; pdc5 (−31, 94)::PGAL2>ERG12>TNAT5–PTEF2>ERG8>TIDP1–TPRM9<MVD1<PADH2−TRPL15A<IDI1<PTEF1-TRP1
This work
N391DA o391 derivative; ERG9(1333, 1335)::CLN2PEST-TURA3-loxP-KlURA3-loxP gal80::loxP-kanMX4-loxP [pJT9R] This work
oJ3 CEN.PK113-5D derivative; gal80::loxP-kanMX4-loxP This work
GH4J3 oJ3 derivative; ura3 (1, 704)::KlURA3 This work
G89J3 oJ3 derivative; ura3 (1, 704)::KlURA3-PTEF1-yEGFP This work
GB5J3 oJ3 derivative; ura3 (1, 704)::KlURA3-PGAL1-yEGFP This work
GB6J3 oJ3 derivative; ura3 (1, 704)::KlURA3-PGAL10-yEGFP This work
GQ3J3 oJ3 derivative; ura3 (1, 704)::KlURA3-PGAL2-yEGFP This work
GQ4J3 oJ3 derivative; ura3 (1, 704)::KlURA3-PGAL7-yEGFP This work
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is depleted and cells have shifted to the ethanol growth 
phase [33]. Strain N6D exhibited half the specific growth 
rate (μmax of 0.16 ±  0.03  h−1) of the wild-type CEN.PK 
reference strain (μmax of 0.30 ± 0.01 h−1) [23]. We pre-
sume that this is due to the metabolic burden from high 
expression levels of the heterologous synthetic pathway 
in the exponential phase. Furthermore, the decreased 
expression level after the diauxic shift might lead to low 
productivities in the post-exponential phase. To exam-
ine productivity across the fermentation period, 24- and 
72-h samples were re-analysed using a new HPLC–UV 
method. Consistent with the GC–MS data obtained pre-
viously [23], a titre of 125 ± 30 mg L−1 was measured at 
72 h. At 24 h, the titre was 82 ± 37 mg L−1 (Fig. 2b) and 
the productivity was calculated to 5.7  mg  g−1 biomass 
h−1 in the exponential phase (from 0 to 24 h) compared 
to only 0.18 mg g−1 biomass h−1 in the post-exponential 
phase (from 24 to 72 h).
The decreased nerolidol production rate may be 
attributed to the lower promoter activity we previ-
ously reported for these constitutive promoters during 
the ethanol phase [33]. Indeed, the mRNA levels of the 
genes for nerolidol production (EfmvaS, EfmvaE, ERG12, 
ERG8, MVD1, IDI1, ERG20 and AcNES1) decreased 
3- to 10-fold in the ethanol growth phase compared to 
the exponential growth phase (Fig. 2d). As noted previ-
ously [23], the mRNA levels of the reference genes ACT1 
and PDC1 also decreased. Interestingly, in contrast to 
the classical ‘housekeeping’ genes ACT1 and PDC1, 
acetyl-CoA synthase (ACS2) exhibited similar transcrip-
tional levels in the exponential/ethanol growth phases.
Copper‑inducible expression improves nerolidol 
production
To avoid both the metabolic imbalances causing 
decreased growth rate in the exponential phase and 
the decreased productivities in the post-exponential 
phase, gene expression can be controlled using an 
induction system. The CUP1 promoter is responsive to 
copper ion concentration [38]. In the absence of addi-
tional copper, the CUP1 promoter exhibits a moderate 
expression level; with addition of high-concentration 
copper (above 100  μM), activity is induced to a level 
comparable to the strong TEF1 promoter in exponen-
tial phase [33]. In contrast to the TEF1 promoter, the 
CUP1 promoter can maintain high expression activity 
in the ethanol phase (in the presence of 300  μM cop-
per; [33]). These characteristics make the CUP1 pro-
moter an potentially useful candidate to address both 
of the aforementioned problems. To test the effect 
on sesquiterpene production, a new set of plasmids 
were constructed (Table  2): an E. faecalis upper MVA 
pathway plasmid (pPMVAgw) with EfmvaS and Efm-
vaE controlled by two divergent CUP1 promoters; a 
yeast lower MVA pathway plasmid (pPMVAd36) with 
the mevalonate kinase gene ERG12 controlled by the 
CUP1 promoter and the other three genes (ERG8-
phosphomevalonate kinase, MVD1-mevalonate 
Table 2 Plasmids used in this work
Symbol > or < indicates the direction of open reading frame
Plasmid Features Reference
pRS423 E. coli/S. cerevisiae shuttle plasmid; 2 μ, HIS3 [45]
pRS424 E. coli/S. cerevisiae shuttle plasmid; 2 μ, TRP1 [45]
pRS425 E. coli/S. cerevisiae shuttle plasmid; 2 μ, LEU2 [45]
pPMVAu8 pRS423: PRPL4A>EfmvaS>TEFM1–PRPL15A>EfmvaE>TEBS1 [23]
pPMVAd3 pRS424: PRPL8B>ERG12>TNAT5–PSSB1>ERG8>TIDP1–PRPL3>MVD1>TPRM9–PYEF3>IDI1>TRPL15A [23]
pJT1 pRS425: PTEF2>ERG20>TRPL3–PTEF1–AcNES1-TRPL41B [23]
pPMVAugw pRS423: TEFM1<EfmvaS<PCUP1–PCUP1>EfmvaE>TEBS1 This work
pIMVAu1 pRS423: HMG2 (−309, −153)-HIS3-TEFM1<EfmvaS<PGAL1–PGAL10>ACS2>TACS2–PGAL2>EfmvaE>TEBS1–PGAL7>HMG2K6R(1,292) This work
pPMVAd36 pRS424: PCUP1>ERG12>TNAT5–PTEF2>ERG8>TIDP1–TPRM9<MVD1<PTEF2–TRPL15A<IDI1<PTEF1 This work
pIMVAd39T pUC19: pdc5 (−277, −32)-PGAL2>ERG12>TNAT5–PTEF2>ERG8>TIDP1–TPRM9<MVD1<PADH2–TRPL15A<IDI1<PTEF1-TRP1-pdc5 (95,373) This work
pJT3 pRS425: TRPL3<ScERG20<PCUP1–PCUP1>AcNES1>TRPL41B This work
pJT9R pRS425: TRPL3<ScERG20<PGAL1–PGAL2>AcNES1>TRPL41B This work
pILGFP3 Yeast integration plasmid; yEGFP without promoter [33]
pILGH4 pILGFP3: with yEGFP removed [33]
pILGB5A pILGFP3: PGAL1-yEGFP [33]
pILGB6 pILGFP3: PGAL10-yEGFP This work
pILGFPQ3 pILGFP3: PGAL2-yEGFP This work
pITGFPQ4 pILGFP3: PGAL7-yEGFP This work
Page 5 of 16Peng et al. Biotechnol Biofuels  (2017) 10:43 
pyrophosphate decarboxylase and IDI1-Isopentenyl 
diphosphate:dimethylallyl diphosphate isomerase) con-
trolled by a TEF1 promoter and two TEF2 promoters, 
respectively; and finally, a nerolidol synthetic plasmid 
(pJT3) with ERG20 and AcNES1 controlled by two 
divergent CUP1 promoters (Fig.  2a). The three plas-
mids were co-transformed into the Erg9p-destabilized 
strain oH5 [23] to generate strain NC1D (Table 1).
While the wild-type growth rate (μmax = 0.30 ± 0.01 h−1) 
was not fully recovered, strain NC1D exhibited a 1.6-fold 
faster growth rate (μmax  =  0.25  ±  0.01  h−1) than strain 
N6D (Table  3), demonstrating that the metabolic imbal-
ance in the exponential phase was partially relieved. Fur-
thermore, higher nerolidol production was achieved, 
with a titre of 111 ± 26 mg L−1 at 24 h and 245 ± 8 mg 
L−1 at 72  h (Fig.  2b, c). This equates to production rates 
of 5.1 mg g−1 biomass h−1 in the period from 0 to 24 h, 
slightly lower than the rate in strain N6D; and 0.77 mg g−1 
biomass h−1 in the post-exponential phase (from 24 to 

























































































Fig. 2 Characterizing strains N6D (with “constitutive” gene overexpression constructs) [23] and NC1D (with copper-inducible gene overexpression 
constructs): a the copper-inducible expression cassettes in plasmids pPMVAugw, pPMVAd36 and pJT3; b nerolidol titre at 24 and 72 h; c growth 
curves over batch cultivation; d mRNA levels in strain N6D in the exponential phase (EXP) and the ethanol phase (ETH, at 48 h); e mRNA levels in the 
strain NC1D in the pre-culture (without adding copper; un-induced) and in two-phase cultivation (with copper added; induced; at 10 or 36 h). Two-
phase flask cultivation on 20 g L−1 glucose was employed; for the cultivation of NC1D, 100, 100 and 200 μM (final concentration) copper sulphate 
was added sequentially at 5, 10 and 24 h. mRNA levels were measured by quantitative real-time PCR. Mean values ± standard deviations are shown 
(N ≥ 3)
Table 3 The maximum growth rate (μmax) and  nerolidol 
productivities of the engineered strain in flask cultivation 
on 20 g L−1 glucose
Mean values ± standard deviations are shown (N ≥ 2)
Strain N6D NC1D N391DA
μmax (h
−1) 0.16 ± 0.03 0.25 ± 0.01 0.27 ± 0.01
rnerolidol (0–24 h; mg g
−1 
biomass h−1)
5.73 ± 2.19 5.14 ± 1.29 1.40 ± 0.05
rnerolidol (24–72 h; mg g
−1 
biomass h−1)
0.18 ± 0.08 0.77 ± 0.09 2.10 ± 0.02
Nerolidol titre (72 h; mg L−1) 124 ± 29 245 ± 8 393 ± 3
Nerolidol C-mole yield (%) 1.7 ± 0.4 3.3 ± 0.1 5.0 ± 0.3
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To verify the relationship between gene expression lev-
els and nerolidol production, the mRNA levels in strain 
NC1D were also analysed. Unexpectedly, the mRNA lev-
els for four genes from the ‘lower’ MVA pathway (ERG12, 
ERG8, MVD1 and IDI1; Fig.  2) were similar compared 
to those in the wild-type CEN.PK reference strain [23]. 
Furthermore, the overexpression cassettes could not be 
amplified from the genomic DNA (data not shown). The 
2  μ plasmid originally containing the yeast lower MVA 
pathway was recovered from NC1D. Restriction mapping 
and DNA sequencing showed that DNA recombination 
occurred between pPMVAd36 and pJT3; the result of this 
recombination was a plasmid where the four lower MVA 
pathway gene expression cassettes from pPMVAd36 were 
replaced by the nerolidol synthase cassette from pJT3 
(Additional file 1: Figure S1). This replacement pattern is 
consistent with two homologous recombination events 
occurring, one between the CUP1 promoters for ERG12 
and AcNES1, and one between homologous sequences on 
the plasmid backbones. Despite this undesiriable recom-
bination event, strain NC1D performed better than N6D 
(see above). Very low variability was observed between 
biological replicates for the mRNA levels (Fig.  2e) and 
nerolidol production (Fig.  2b), demonstrating that the 
plasmid recombination and resulting strain were stable.
Despite the loss of the four lower MVA pathway genes, 
the upper pathway genes EfmvaS, EfmvaE and ERG20 
and AcNES1 controlled by CUP1 promoters, were still 
present in NC1D. Consistent with our previous findings 
[33], the mRNA levels for these genes increased by about 
fourfold after copper induction, and high transcript lev-
els were maintained in the ethanol growth phase for 
these genes (Fig. 2e). In the exponential phase under un-
induced conditions, mRNA levels for EfmvaS and Efm-
vaE were 2 and sevenfold lower (Fig. 2e) than transcript 
levels driven by constitutive promoters (Fig.  2d). The 
‘lower’ pathway was not augmented at all, considering the 
loss of the ‘lower’ MVA pathway genes during the recom-
bination event. Together, these data support the idea 
that high transcription of MVA pathway genes during 
the exponential phase (driven by constitutive promoters) 
results in a metabolic imbalance that decreases growth 
rate and nerolidol titre. Applying the CUP1 promoter 
to control synthetic pathway genes improved nerolidol 
production; however, plasmid recombination caused by 
repeated usage of the CUP1 promoter is undesirable in a 
metabolic engineering context. Therefore, an alternative 
inducible expression system was developed.
Δgal80 enables auto‑induction of GAL promoters over/
after diauxic shift
In a previous comparison of a set of commonly used pro-
moters, the GAL1 promoter drove the highest expression 
level [33]. The GAL1 promoter and galactose-based culti-
vation have also been used in the initial laboratory devel-
opment of several sesquiterpene-producing strains [46, 
47]. However, it is not feasible to use galactose as a carbon 
source in industrial production due to its high cost. In the 
core galactose regulon, Gal80p binds the transcription 
activator Gal4p to inhibit Gal4p-mediated transcription 
initiation of the GAL1 promoter in the absence of galac-
tose; in the presence of galactose, transcriptional factor 
Gal3p binds with Gal80p to relieve Gal80p repression on 
Gal4p transcription activation (Fig.  3a) [48]. Galactose-
independent (gratuitous) activation of the GAL1 pro-
moter can be achieved by disruption of the gal80 repressor 
[49]. Additionally, galactose-inducible expression driven 
by GAL1 promoter is co-regulated by Mig1p-mediated 
glucose-dependent repression: in the presence of glucose, 
Mig1p can bind to the GAL1, GAL3 and GAL4 promot-
ers to inhibit gene transcription (Fig. 3a) [48, 50]. Mig1p-
mediated repression can lead to the glucose-dependent 
repression of the GAL1 promoter in a gal80Δ strain [16, 
49, 51]. Consequently, it has been shown that the GAL1 
promoter can be automatically induced in a gal80Δ strain 
as the cells shift to the ethanol growth phase [51].
In the current study, to avoid repeated use of a single pro-
moter for multiple genes, the promoters from the galactose 
metabolic genes (GAL1, GAL10, GAL2 and GAL7) and a 
reference TEF1 promoter were characterized in a gal80Δ 
strain (Tables 1, 2; Fig. 3b). GFP was used as a reporter to 
measure the promoter activities over an entire batch cul-
tivation on 20 g L−1 glucose. Growth profiles were similar 
and showed a diauxic growth pattern in all strains (data for 
the gal80Δ control strain are shown in Fig. 3b; other data 
not shown). We showed previously that, under the same 
conditions, the diauxic shift pattern observed in the growth 
curve was coincident with glucose depletion and the start of 
ethanol consumption, and occurred at ~12 h [33]. Similar 
to our previous study in the wild-type strain [33], activity 
driven by the TEF promoter in the gal80Δ strain decreased 
dramatically during and after the diauxic shift. In contrast, 
the GAL promoters exhibited diauxie-inducible expression 
patterns: their activities started to increase at 12 h, peaking 
at 48 h. The strength of GAL promoters in the post-expo-
nential phase was as follows: PGAL2>PGAL1>PGAL7>PGAL10. 
The auto-inducible expression pattern makes the GAL 
promoter in combination with gal80Δ very useful in strain 
development to simultaneously avoid the metabolic burden 
in the exponential phase and increase productivity in the 
ethanol growth phase.
Auto‑inducible GAL promoter regulation drives efficient 
nerolidol production
To apply the modified galactose-inducible sys-
tem (GAL promoters in gal80Δ background), a new 
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nerolidol-producing strain, N391DA, was constructed 
(Fig. 4a; Tables 1, 2). In the “upper” MVA module, genes 
EfmvaS (HMG-CoA synthase), ACS2 (native acetyl-CoA 
synthase) and EfmvaE (thiolase/HMG-CoA reductase) 
were controlled by PGAL1, PGAL10 and PGAL2, respectively. 
Overexpressing ACS2 has previously been shown to 
increase the intracellular concentration of acetyl-CoA 
[21], which is the precursor metabolite for the MVA path-
way; hence, it was included in the ‘upper’ module. The 
three expression cassettes were integrated into the HMG2 
(HMG-CoA reductase) promoter locus with the selection 
marker HIS3. At the same time, a PGAL7 promoter linked 
to a short sequence of the HMG2 gene including a K6R 
mutation that stabilizes Hmg2p from degradation [52, 
53] was introduced as a fusion with the native HMG2. 
As a result, HMG2K6R was expressed from the genome 
under the control of PGAL7. To construct a “lower” MVA 
module, ERG12 (mevalonate kinase) was controlled by 
PGAL2; the other three genes (ERG8, MVD1, IDI1) were 
controlled by glucose-dependent “constitutive” promot-
ers (PTEF2, PADH1 and PTEF1, respectively). This construct 
was integrated with the TRP1 selection marker into the 
PDC5 locus, which encodes a weakly expressed pyru-
vate decarboxylase [54]. Dysfunction of PDC5 does not 
cause a major change in yeast metabolism, because of 
complementation by isoforms PDC1 and PDC6 [55]. For 
the nerolidol synthesis module, PGAL1-controlled ERG20 
and PGAL2-controlled AcNES1 were introduced on a 2μ 
plasmid. Finally, squalene synthase (Erg9p) was destabi-
lized by the addition of an endoplasmic-reticulum medi-
ated protein degradation sequence to reduce its ability to 
compete for FPP with nerolidol synthase [23], and gal80 
was disrupted to allow diauxic induction of GAL promot-
ers. The resulting strain N391DA was evaluated through 
two-phase flask cultivation.
Strain N391DA exhibited a normal exponential growth 
with μmax of 0.27 ±  0.01  h−1—1.7-fold faster than the 
strain N6D and slightly faster than strain NC1D. Consist-
ent with the yeast diauxic growth model, N391DA con-
sumed glucose and produced ethanol in the exponential 
growth phase, and ethanol was subsequently consumed 
in the secondary growth phase (Fig.  4b). N391DA pro-
duced 38  mg  L−1 nerolidol at 24  h, production rates of 
1.4 mg g−1 biomass h−1 in the period from 0 to 24 h, four-
fold lower than the rate in strain N6D. Nerolidol reached 
392 ± 2 mg L−1 at 72 h, which translates to a production 
rate of 2.1  mg  g−1 biomass h−1 in the post-exponential 
phase (from 24 to 72  h)—12-fold higher than the rate 
in strain N6D (Table 3). The 72 h titre represents a 60% 
improvement relative to NC1D with copper-inducible 
constructs. N391DA exhibited the highest specific nero-
lidol production rate (rnerolidol) between 24 and 48 h and 
86% of nerolidol was produced after 24 h (Fig. 4d).
To verify the expression pattern of the genes controlled 
by the modified galactose-inducible system, the mRNA 
levels were analysed in strain N391DA (Fig.  4c). In the 
exponential phase, the expression levels of the reference 
genes ACT1 and PDA1 in N391DA were similar (two-
tailed t test p > 0.1) to those in strains N6D and NC1D. 
As observed previously, their mRNA levels decreased 
significantly in the ethanol growth phase; this was also 

































































Fig. 3 Schematic representing regulatory networks for the galactose-inducible promoter (PGAL1; a) and GFP fluorescence levels in gal80Δ back-
ground strains (b) with the yEGFP gene driven by PTEF1 (strain G89J3), PGAL1 (strain GB5J3), PGAL10 (strain GB6J3), PGAL2 (strain GQ3J3) and PGAL7 (strain 
GQ4J3). Cultures were grown on 20 g L−1 glucose. GFP fluorescence is expressed as percentage of exponential-phase auto-fluorescence of the 
reference strain (GH4J3). The growth curve (OD600) for GH4J3 is shown. Mean values ± standard deviations are shown (N = 2)
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by TEF1, TEF2 and ADH1 promoters. In contrast, the 
genes controlled by GAL promoters exhibited increased 
transcriptional levels: twofold for ACS2, 11-fold for Efm-
vaS, 22-fold for EfmvaE, 27-fold for HMG2, ninefold 
for ERG12, 26-fold for ERG20 and fourfold for AcNES1 
in the ethanol growth phase, compared to in the expo-
nential growth phase. These fold-changes are consistent 
with the expression pattern of the four GAL promoters as 
characterized above (Fig. 3).
Sucrose as an alternative carbon source for nerolidol 
production
Sucrose from sugar cane/sugar beet is an alternative car-
bon source to glucose in industrial fermentation [56–58]. 
As for the GAL genes, the invertase gene for sucrose uti-
lization (SUC2) is under Mig1p-mediated glucose repres-
sion, which is relieved when yeast is cultivated on sucrose 
[59, 60]. Considering this, it is reasonable to expect that 
the expression output from GAL promoter in gal80Δ 
background strain might be different on sucrose than 
on glucose. To investigate the effect of sucrose on nero-
lidol production, GAL promoter activities in gal80Δ 
background strains and nerolidol production for strain 
N391DA were characterized on sucrose. Yeast strains 
were pre-cultured on 40  g L−1 glucose, which mini-
mized GAL promoter activities in gal80Δ strains (data 
not shown). A 6-h lag phase was exhibited after trans-
ferring to 20  g L−1 sucrose medium; this lag phase was 
seen in both gal80Δ strains and the GAL80 control strain 
(Fig.  5a; Additional file  1: Figure S2). During the lag 
phase on sucrose, glucose repression on GAL promot-
ers was relieved. GFP expression driven by the GAL1 and 
GAL2 promoters increased sharply during the lag phase 
and plateaued during exponential growth (Fig.  5a); this 
expression level was similar to that observed in the etha-














































































































Fig. 4 Characterizing strain N391DA with gal80Δ-GAL promoter constructs: a genetic modules/plasmid for the “upper” mevalonate pathway (pIM-
VAu1), the “lower” mevalonate pathway (pIMVAd39T) and the nerolidol synthetic genes (pJT9R); b, d metabolic and growth profiles (N = 2); c mRNA 
levels (N = 3) in the exponential phase (EXP) and the ethanol growth phase (ETH, at 36 h). Two-phase flask cultivation on 20 g L−1 glucose was 
employed. Mean values ± standard deviations are shown
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further increase of ~twofold was observed after 24 h, pre-
sumably after the diauxic shift (Fig. 5a).
To characterize nerolidol production on sucrose, strain 
N391DA was first pre-cultured on 40 g L−1 glucose and 
then cultivated on 20  g  L−1 sucrose. N391DA exhibited 
a 48-h lag phase on sucrose (Fig. 5b), dramatically longer 
than that for the GFP strains (Fig.  5a). The sugar pro-
file demonstrated that strain N391DA first fermented 
sucrose and its hydrolysate products (glucose and fruc-
tose) into ethanol; the diauxic shift occurred by 72  h, 
and the strain then re-used ethanol in the post-expo-
nential phase (Fig. 5b). In sucrose batch cultivation, the 
final nerolidol titre was 632 ± 57 mg L−1, 1.6-fold higher 
than in glucose batch cultivations. In addition, N391DA 
exhibited the highest post-exponential-specific nerolidol 
production rate of 5  mg  g−1 biomass h−1 (Fig.  5c com-
pared to Fig. 4d).
Nerolidol production in fed‑batch cultivation
To achieve high-titre nerolidol production for strain 
N391DA, fed-batch strategies were explored. We first 
explored a strategy designed to ensure that (a) ferment-
able sugars are catabolized through respiratory metab-
olism and (b) cultures are maintained under aerobic 
conditions. The initial feed rate was set to 1  mM glu-
cose  g−1 biomass  h−1 with 600  g  L−1 glucose feeding 
medium and then exponentially increased with a rate of 
0.05  h−1; the feeding was switched off when dissolved 
oxygen (DO) was below 25% and maximum agitation and 
gassing were achieved, and the feeding was re-triggered 
when DO was above 30% (Additional file 1: Figure S3a). 
Two additional experiments were performed using volu-
metrically similar initial feed rates and feed solutions of 
600 g L−1 sucrose and 400 g L−1 glucose/158 g L−1 etha-
nol, respectively.
In the three experiments, the respiration quotients 
fluctuated around 1 for glucose or sucrose feeding pro-
cesses, and around 0.9 for glucose/ethanol feeding pro-
cess (Additional file 1: Figure S4), demonstrating that the 
fermentable sugars were catabolized through respiration. 
All processes began in batch mode using 20  g L−1 glu-
cose as a carbon source and proceeded through diauxie 
and into the ethanol growth phase until DO started in 
increase sharply, triggering the feed. In this batch period, 
the three cultures produced 406 ± 57 mg L−1 nerolidol at 
30 h (Fig. 6a). In the subsequent feeding phase, the glu-
cose/ethanol feed provided higher nerolidol production 
than glucose or sucrose feeding;  >2  g L−1 nerolidol was 
achieved at 102 h for glucose/ethanol and this titre was 
not achieved until 150 h for glucose and sucrose feeding. 
The final titre for the glucose/ethanol feed was >3 g L−1 
at 174 h. For all three fed-batch experiments, the specific 
nerolidol production rates during feeding were lower 
than the rate observed in the ethanol growth phase in 
the batch process (Fig. 6a). The C-mole yield at 102 h was 
2.0 ± 0.4% in these three fed-batches.
Next, the feeding strategy was altered with the aim 
to maintain overflow metabolism and cycling between 























































































































Fig. 5 Effects of sucrose on GAL promoter activities in gal80Δ 
background and nerolidol production for strain N391DA: a the 
fluorescence levels of the yEGFP controlled by GAL1 (strain GB5J3) 
or GAL2 (strain GQ3J3) promoter over the batch cultivation on 20 g 
L−1 sucrose and the growth profile (OD600) of strain GH4J3; b, c 
metabolic and growth profile for strain N391DA in two-phase flask 
cultivation on 20 g L−1 sucrose. Vertical dashed lines indicate the end 
of lag phase. Mean values ± standard deviations are shown (N = 2)
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Figure S3b). After the batch phase, exponential feeding 
with an initial feeding rate of 3 mM glucose g−1 biomass 
h−1 for 600  g  L−1 glucose (or volumetrically the same 
for 600  g  L−1 sucrose) feeding medium and a specific 
increasing rate of 0.05 h−1 were applied. Once 50 g L−1 
sugar had been fed, the feeding was paused to allow cells 
to consume the ethanol produced during sugar fermen-
tation. Subsequently, 10 or 20  g L−1 sugar pulse feed-
ing was repeatedly triggered by sharp DO increases 
(Additional file 1: Figure S5). The production of ethanol 
was confirmed by the respiration quotient being over 2 
when the sugar was fed (Additional file 1: Figure S5). In 
the batch phase for the three batches, 404 ± 11 mg L−1 
nerolidol was produced (Fig.  6b), consistent with the 
above results (Fig. 6a). In these three fed-batch processes 
(Fig. 6b), >4 g L−1 nerolidol was produced at 96 h, and the 
specific nerolidol production rates in the early feeding 
phase (t < 96 h) were noticeably higher than those in the 
carbon-restricted processes (Fig. 6a). At 96 h, the C-mole 
yield was 3.8  ±  0.1% in the two glucose-overflow fed-
batches and 4.5% in the sucrose-overflowed fed-batch 
(Fig. 6b).
Discussion
An efficient sesquiterpene-producing yeast platform 
is of broad industrial interest, because it can be applied 
for the production of various high-value sesquiterpenes 
as well as FPP-derived biofuels by simply substituting a 
specific terpenoid production pathway (Fig.  1). There 
are two key principles for increasing FPP availability for 
sesquiterpene production in yeast: enhancing the MVA 
pathway to increase precursor supply, and reducing 
squalene synthase activity to decrease its consumption of 
FPP [14, 17–19, 23, 26, 27, 51, 61]. This study aimed to 
couple the transcriptional regulation pattern of heterolo-
gously expressed pathway genes to bioprocess conditions 
to minimize metabolic imbalance and optimize heterolo-
gous sesquiterpene production.
In previous studies, constitutive promoters were most 
often used to control the expression of heterologous 
genes, whereas the optimization of expression strength 
over the different fermentation stages has not been well 
investigated [7, 8]. In the current study, three catego-
ries of transcription regulation patterns were applied to 
assemble synthetic pathways: constitutive, copper-induc-
ible and diauxie-induced. Using reporter gene systems, 
we showed previously that expression outputs from con-
stitutive promoters (including “classical” translational 
elongation factor promoters, PTEF1 and PTEF2; glycolytic 
promoter, PADH1; ribosome biogenesis promoters, PRPL3, 
PRPL15A) dramatically decrease after the diauxic shift [33]. 
Our transcription data (Fig. 2d) and nerolidol production 
data (Fig. 2b) confirmed this. Nerolidol is not toxic and 
does not cause dramatic growth inhibition (Additional 
file 1: Figure S6), in contrast to monoterpenes [62]. But 
we also observed a decreased growth rate (Fig. 2c), which 
was consistent with metabolic burden from high-level 
expression in the exponential phase.
Using a copper-inducible promoter (PCUP1), gene expres-
sion was shifted from exponential to the ethanol growth 
phase (Fig.  2e). This resulted in improved growth rate 
























































































Fig. 6 Nerolidol production for strain N391DA in fed-batch cultivations: a nerolidol production (solid line) and specific production rate (r; dashed 
line) in carbon-source-restricted DO-triggered fed-batch cultivation with feeding carbon source of 600 g L−1 glucose (R-Glc), or 600 g L−1 sucrose 
(R-Suc), or 400 g L−1 glucose 158 g L−1 ethanol mixture (R-Glc/Eth); b nerolidol production (solid line) and specific production rate (r; dashed line) in 
carbon-source-overflowed/carbon-source-pulsing fed-batch cultivation with feeding carbon source of 600 g L−1 glucose (with 10 g L−1 glucose 
pulse, O10-Glc; with 20 g L−1 glucose pulse, O20-Glc) or 600 g L−1 sucrose (with 20 g L−1 sucrose pulse, O20-Suc). Vertical dashed line approximately 
indicated the start of feeding. Growth and process values refer to Additional file 1: Figures S4, S5. N = 1
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productivities after the diauxic shift (Fig. 2b). However, the 
repeated use of the CUP1 promoter sequence led to unde-
sirable homologous recombination and loss of introduced 
DNA fragments (Additional file  1: Figure S2). It is likely 
that similar losses have occurred previously when repeated 
promoter sequences have been used, for example, Beek-
wilder et al. [63] observed that almost half of colonies did 
not produce a carotenoid reporter product when they used 
the TDH3 promoter to control several carotogenic pathway 
genes. Genetic instability at repeat sequences has been doc-
umented in yeast [64], and provides a challenge for large-
scale modification/introduction of metabolic pathways due 
to limited availability of appropriate promoters [33].
To address this problem, we characterized four native 
GAL promoters (PGAL1, PGAL10, PGAL2 and PGAL7) in a 
gal80Δ genetic background to engineer a diauxie-inducible 
system [16, 65], and applied them to assemble the MVA 
pathway modules (Figs.  3, 4a). While these promoters in 
gal80Δ background have been used to control the expres-
sion of the genes from the MVA pathway and amorpha-
diene/isoprene synthetic pathway previously [16, 65], 
they have not been characterized in terms of behaviour 
throughout the fermentation nor have they been ranked. 
The relative strength of PGAL1 and PGAL10 has been exam-
ined previously with conflicting results. One study [41] 
observed PGAL10 to be stronger than PGAL1; in contrast, our 
study and two others [39, 66] showed PGAL1 to be stronger 
than PGAL10. It is possible that differences in experimental 
conditions caused this discrepancy. Using the GAL pro-
moters, a further shift in gene expression from exponential 
to ethanol growth phase was achieved (Figs. 2e, 4c), which 
resulted in further improved growth during the exponential 
phase (Fig.  4b) and further improved productivities after 
the diauxic shift (Figs. 2b, 4d). Increased expression from 
the GAL promoters and improved nerolidol productivities 
were consistently observed when the engineered cells were 
cultivated on sucrose (Fig. 5). Together, these data demon-
strate the importance of appropriate transcriptional control 
modules for optimized strain engineering. There are several 
genotypic differences between strains NC1D and N391DA, 
including promoter identity (PCUP1 vs. PGAL), gene location 
(plasmid vs. genome integration) and gene expression level; 
and we have not examined each in detail to determine rela-
tive contribution to the phenotype.
In a previous study using the gal80Δ background, the 
sesquiterpene amorphadiene was produced at  >40  g L−1 
titre in ethanol fed-batch cultivation, whereas it reached 
only ~3 g L−1 in glucose fed-batch cultivation [16]. Here, 
nerolidol production in fed-batch cultivation was also 
investigated in the gal80Δ background; in contrast to the 
previous study, two substrate-feeding strategies, sugar-
restricted and sugar-surplus, were compared (Fig.  6). In 
the sugar-restricted feeding processes, sugar was expected 
to be catabolized through respiratory metabolism; in the 
sugar-surplus feeding processes, ethanol was expected 
to accumulate in the sugar respiro-fermentative metabo-
lism after each sugar feed and to be re-consumed when 
sugar was depleted. The two feeding strategies resulted in 
similar growth profiles (comparing OD600 when t  ≤  102 
or 96  h; Additional file  1: Figures S4, S5). However, in 
the carbon-overflow fed-batches, higher titre/yield/rate 
of nerolidol were achieved, compared to the substrate-
restricted fed-batches (Fig. 6). In addition to different pro-
moter behaviours throughout the fed-batch cultivation, 
the improvement in nerolidol production might be due 
to a MVA pathway response to “overflow” metabolism, 
as is seen in ethanol/acetate/glycerol production through 
glycolysis [67–69]. In support of this possibility, the con-
centrations of intracellular pyruvate, acetyl-CoA, acetoa-
cetyl-CoA and FPP were shown to increase as the dilution 
rate increased in carbon-limited chemostat processes [70, 
71]. The pyruvate node is a key metabolic node for regula-
tion of carbon flux in yeast; specifically, it determines flux 
towards mitochondrial pyruvate dehydrogenase or the 
cytosolic pyruvate dehydrogenase bypass (and ultimately, 
acetyl-CoA, which provides substrate for the MVA path-
way) [72, 73]. Moreover, flux distribution into the cytosolic 
pyruvate dehydrogenase bypass decreases with decreased 
glucose feeding rate [74]. This can explain the decreased 
flux through the MVA pathway for nerolidol production 
under the carbon-limited fed-batch.
Conclusion
Here, we present an expanded modular genetic regu-
latory system to co-ordinate expression outputs with 
physiological behaviour of engineered cells under indus-
trially relevant cultivation conditions. The gene tran-
scriptional regulatory pattern for assembled metabolic 
pathways is critically important for metabolic function-
ality and optimal productivity in engineered strains. This 
principle should be considered for de novo assembly of 
heterogeneous metabolic pathways in the “design-build” 
construction cycle for industrial microbial producers. 
The diauxie-induction system, including the four char-
acterized GAL promoters, is simple and efficient for 
developing a yeast strain for high-level sesquiterpene 
production. Further optimization to balance sugar and 
ethanol growth phases might significantly increase titres.
Methods
Plasmid and strain construction
Strains used in this work are listed in Table 1 and plasmids 
are listed in Table  2. Primers used in polymerase chain 
reaction (PCR) and details of PCR performed in this work 
are listed in Additional file 1: Table S1. Plasmid construc-
tion processes are listed in Additional file 1: Table S2.
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Strain NC1D was generated by co-transforming plas-
mids pPMVAugw, pPMVAd36 and pJT3 into the Erg9p-
destabilized strain oH5 (ERG9-yEGFP-CLN2PEST) [23]. 
Strain o391D was generated by sequentially transforming 
strain CEN.PK2-1C [44] with PmeI-digested pIMVAd39T, 
SwaI-digested pIMVAu1 and an Erg9p-destabilization 
fragment (ERG9C-terminal-CLN2PEST-TURA3-loxP-KlURA3-
loxP-TERG9; Additional file 1: Table S1#21; [23]). The nero-
lidol production plasmid pJT9R was then transformed 
into strain o391D. Finally, gal80 was disrupted by integrat-
ing a LoxP-KanMX4-loxP marker (Additional file 1: Table 
S1#23) to generate strain N391DA. N391DA was selected 
on SC-glutamate-high-glucose (SCGHG) agar plate with 
300  μg  mL−1 G-418. The nutrient recipe of the SCGHG 
agar is as follows: 1.6  g L−1 uracil-drop-out amino acid 
mixture [75], 1.7 g L−1 yeast nitrogen base (YNB) without 
ammonium sulphate (Sigma-Aldrich#Y1251), 1 g L−1 glu-
tamate, 200 g L−1 glucose. For strains NC1D and N391DA, 
at least 3 independent colonies were stored separately in 
20% glycerol at −80 °C for subsequent evaluation.
To disrupt gal80, a LoxP-KanMX4-loxP PCR fragment 
(Additional file  1: Table S1#23) was transformed into 
CEN.PK113-5D; the resultant strain oJ3 was transformed 
with SwaI-digested pILGH4, pILG89S, pILGB5AS, pIL-
GB6S, pILGQ3 and pILGQ4 to generate strain GH4J3, 
GB5J3, GB6J3, GQ3J3 and GQ4J3, respectively.
Two‑phase flask cultivation and sampling
Nerolidol-producing strains were evaluated through 
two-phase flask cultivation using dodecane as a 
non-toxic organic extractant phase [76]. Synthetic 
minimal (SM) medium containing 6.7  g L−1 YNB 
(Sigma-Aldrich #Y0626; pH 6.0) with 20  g L−1 glucose 
as the carbon source was used (SM-glucose). 100  mM 
2-(N-morpholino) ethanesulfonic acid (MES, Sigma-
Aldrich#M8250) was used to buffer medium pH and 
the initial pH was adjusted to 6.0 by adding ammonium 
hydroxide. Strains were recovered from glycerol stocks by 
streaking on SM-glucose agar plates (for N6D and NC1D) 
or SCGHG agar plates (for N391DA) and pre-cultured in 
MES-buffered SM 20 g L−1 glucose (or 40 g L−1 glucose 
as indicated) medium to exponential phase (cell density 
OD600 between 1 and 4). Pre-cultured cells were collected 
by centrifugation and re-suspend in fresh media before 
initiating two-phase cultivations. Two-phase flask culti-
vation was initiated by inoculating pre-cultured cells to 
OD600 = 0.2 in 25 mL MES-buffered SM 20 g L−1 glucose 
medium (or 23  mL MES-buffered SM 20  g  L−1 sucrose 
medium when cultures were not sampled for RNA extrac-
tion) in 250  mL flasks with solvent-resistant screw-caps 
[76]; 2 mL dodecane was added to extract nerolidol. Flask 
cultivation was performed at 30°C and 200  rpm. For all 
cultivations, about 3 mL culture was sampled before the 
end of exponential growth phase for OD measurement; 
meanwhile, dodecane and culture were sampled in 1:10 
ratio for metabolite analysis (see below). For RNA extrac-
tion, 2 mL exponential-phase culture (OD600 = 1–1.5) and 
1 mL ethanol growth-phase culture (at 36 or 48 h) were 
sampled, and cells were collected and stored at −80 °C.
Fed‑batch cultivation
Fed-batch cultivation was performed in DASGIP 400-
mL fermenters (DASGIP#SR0400SS, Jülich, Germany). 
The medium for fed-batch cultivation was modified from 
previous reports [16, 77, 78]. 1×  trace element compo-
sition and 1× vitamin composition from previous report 
[77] were used. Seed and batch media contained 15 g L−1 
(NH4)2SO4, 8 g L−1 KH2PO4, 3 g L−1 MgSO4, 10× trace 
element composition and 10×  vitamin composition; 
additionally, seed medium contained 40  g  L−1 glucose, 
and batch medium contained 20  g  L−1 glucose. Feed 
medium contained 9  g  L−1 KH2PO4, 2.5  g  L−1 MgSO4, 
3.5 g L−1 K2SO4, 0.28 g L−1 Na2SO4, 10×  trace element 
composition and 10×  vitamin composition, with car-
bon source of 600  g  L−1 glucose, or 600  g  L−1 sucrose, 
or a mixture of 400 g L−1 glucose and 158 g L−1 ethanol. 
Ammonium hydroxide (~10  M) was used to adjust pH 
value to 5. Dissolved oxygen (DO) was monitored using 
a PreSens minisensor oxygen metre (PreSens, Germany) 
and controlled with a  proportional–integral (PI; DO 
set-point, 30%; P, 0.5; Ti, 50  s; PI output, 0–100%) agi-
tation-gassing-cascade (PI input 0–60%  ~agitation out-
put 300–600  rpm; PI input 20–60%  ~air gassing output 
1.58–3.16 L  h−1) controller (DASGIP control). Off-gas 
was dried using a 10 °C chiller and 50 mL self-indicating 
silica gel was analysed using the DASGIP off-gas analyser.
In batch cultivation, 130 mL batch medium and 25 ml 
dodecane were used initially; seed culture in exponen-
tial phase (OD600  =  5–10) was directly inoculated to 
OD600 = 0.2 in batch culture. Medium feeding was trig-
gered when the DO increased sharply after carbon 
sources in batch medium were depleted. Medium feed-
ing was programmed using the DASGIP VB.NET script 
feeding controller (for feeding script logic charts refer to 
Additional file 1: Figure S3).
Quantitation of mRNA level
Total RNA was extracted using a yeast RiboPure™ RNA 
Purification Kit (Ambion #AM1926) or a TRIzol® Plus 
RNA Purification Kit (Ambion #12183555). After DNase 
treatment, 0.1 or 0.2  μg total RNA was used for first-
strand cDNA synthesis in a 10  μL reaction using Proto-
Script® II Reverse Transcriptase (NEB #M0368). The 
diluted cDNA was used as the template for quantitative 
real-time (qRT) PCR (primers are listed in Additional 
file  1: Table S1#29 to #40). KAPA SYBR®  FAST qPCR 
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Kit (Kapa Biosystems#KP-KK4601) and CFX96 Touch™ 
Real-Time PCR Detection System (BIO-RAD) were used 
in qRT-PCR. Yeast genomic or plasmid DNA was used to 
prepare the standard curve. Ct values were analysed using 
CFX Manager Software (Bio-Rad Laboratories, QLD Aus-
tralia). The mRNA levels (N pg−1 total RNA) were calcu-
lated by referring to the standard curve equations.
GFP fluorescence assay
To monitor GFP fluorescence over the entire batch cultiva-
tion, cells were cultivated aerobically in MES-buffered 20 mL 
SM-glucose (SM-sucrose) medium in 100  mL flasks. Sam-
ples were taken at indicated time points, and GFP fluores-
cence in single cells was analysed immediately after sampling 
using a flow cytometer (BD Accuri™ C6; BD Biosciences, 
USA). Cultures were diluted after 12 h by 10 volume water 
for flow cytometer analysis. GFP fluorescence was excited by 
a 488 nm laser and monitored through a 530/20 nm band-
pass filter (FL1.A); 10,000 events were counted per sample. 
The GFP fluorescence signal (FL1.A) was corrected accord-
ing to the values of FSC.A (forward scatter detector) and 
SSC.A (side scatter detector) [33]. GFP fluorescence level 
was expressed as the percentage relative to the average back-
ground auto-fluorescence from exponential-phase cells of a 
GFP-negative reference strain GH4J3.
Metabolite analysis
Extracellular metabolites were analysed by the Metabo-
lomics Australia Queensland Node. Trans-nerolidol was 
analysed using a novel HPLC method. Dodecane sam-
ples (in some cases, diluted with dodecane) were diluted 
in 40-fold volume of ethanol. Ethanol-diluted dodecane 
samples of 20 μL were injected into a Zorbax Extend C18 
column (4.6 × 150 mm, 3.5 µm, Agilent PN: 763953-902) 
with a guard column (SecurityGuard Gemini C18, Phe-
nomenex PN: AJO-7597). Analytes were eluted at 35  °C 
at 0.9 mL/min using the mixture of solvent A (high purity 
water, 18.2 kΩ) and solvent B (45% acetonitrile, 45% meth-
anol and 10% water), with a linear gradient of 5–100% sol-
vent B from 0 to 24 min, then 100% from 24 to 30 min and 
finally 5% from 30.1 to 35 min. Analytes of interest were 
monitored using a diode array detector (Agilent DAD SL, 
G1315C) at 196 and 202 nm wavelengths. Spectral scans 
were also performed on each of the compounds from 190 
to 400 nm in steps of 2 nm to confirm their identity and 
purity. Trans-nerolidol primary pharmaceutical reference 
standard (93.7% purity; Sigma-Aldrich #04610590) was 
used to prepare the standard curve for quantification.
Glucose, ethanol, acetate, glycerol and mevalonate were 
analysed through ion-exclusion chromatography [79]. 
Ion-exclusion chromatography was performed using an 
Agilent 1200 HPLC system and an Agilent Hi-Plex H col-
umn (300  ×  7.7  mm, PL1170-6830) with guard column 
(SecurityGuard Carbo-H, Phenomenex PN: AJO-4490). 
Analytes were eluted isocratically with 4  mM H2SO4 at 
0.6 mL/min at 65  °C. Glucose, ethanol, glycerol and meva-
lonate were monitored using a refractive index detec-
tor (Agilent RID, G1362A); acetate and mevalonate were 
detected using an ultraviolet–visible light absorbance detec-
tor (Agilent MWD, G1365B) at 210  nm. For sucrose, glu-
cose and fructose analysis, analytes were eluted isocratically 
using high purity water (18.2 MΩ cm) as the mobile phase, 
at 0.4 mL/min for 21 min, and sugars (sucrose, glucose and 
fructose) were monitored using a refractive index detector 
(Agilent RID, G1362A).
Physiological feature calculation
Physiological parameters were calculated as reported 
previously [80]: the maximum growth rates are the lin-
ear regression coefficients of the ln OD600 versus time 
during the exponential growth phase; one unit of OD600 
equals 0.23 g L−1 biomass; the specific production rate of 
nerolidol (rnerolidol, mg  g−1 biomass h−1) was calculated 
by dividing Δ nerolidol titre (mg L−1) with the integral of 
biomass (g L−1) in defined time (h).
Additional file
Additional file 1: Table S1. Primers and PCR fragments amplified/used 
in this work. PXXX, promoter of gene XXX; TXXX, terminator of gene XXX; 
Y-GDNA, CEN.PK113-7D genomic DNA; sequence annealing to template 
in primers is shown in red and italics; over-lap sequence for over-lap 
extension PCR and Gibson Assembly is underlined; restriction sites used in 
cloning are shown in bold. Table S2. Molecular construction of plasmids 
used in this work. Figure S1. Plasmid rearrangement in the strain NC1D. 
Plasmid pPMVAd36 and [TRP1] from NC1D were digested by restriction 
enzymes NotI, SalI, SphI, BamHI and SbfI and gel figure was shown as the 
right-bottom figure. Figure S2. The growth profile of strain GH4 [CEN.
PK113-5D derivative; ura3(1, 704 )::KlURA3] (1) on sucrose. The cells were 
pre-cultured on 40 g L-1 glucose. Mean values from duplicate experi-
ments are shown. Figure S3. Logic charts for fed-batch feeding scripts: 
(a) carbon-source-restricted/DO-triggered fed-batch cultivation; (b) 
carbon-source-overflowed/carbon-source-pulsing fed-batch cultivation. 
Fs, feeding flow storage value; DOt, dissolved oxygen on-line value at 
time t; DOL, lowest dissolved oxygen storage value; T1, storage time; t, 
on-line time; μ, specific rate of feeding flow increasement; N, agitatation 
speed; Nmax, the maxium agitation speed; FVs, feeding volume storage 
value; FVt, feeding volume on-line value; Vt, culture volume on-line value. 
Figure S4. Growth (OD600) and process values (Dissovled oxygen, DO; 
oxygen transfer rate, OTR; carbon transfer rate; CTR; respiration quotient, 
RQ) in fed-batch cultivation for strain N391DA, with feeding logics in Fig. 
S1a employed. (a&b), 600 g L-1 glucose feeding; (c&d), 600 g L-1 sucrose 
feeding; (e&f ), 400 g L-1 glucose and 158 g L-1 ethanol feeding. Figure 
S5. Growth (OD600) and process values (Dissovled oxygen, DO; oxygen 
transfer rate, OTR; carbon transfer rate; CTR; respiration quotient, RQ) in 
fed-batch cultivation for strain N391DA, with feeding logics in Fig. S1b 
employed. (a&b), 600 g L-1 glucose feeding with 10 g L-1 glucose pulse; 
(c&d), 600 g L-1 glucose feeding with 20 g L-1 glucose pulse; (e&f ), 600 g 
L-1 sucrose feeding with 20 g L-1 sucrose pulse. Figure S6. The influence 
of nerolidol on yeast growth. Synthetic minimal medium was used, which 
contained 6.7 g L-1 yeast nitrogen base (Sigma-Aldrich #Y0626; pH 6.0) 
and 20 g L-1 glucose. Isomer-mixed nerolidol (Sigma-Aldrich #H59605) was 
used. Tween 80 was added to homogenize nerolidol into liquid medium. 
Mean values ± standard deviations are shown (N = 3).
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